591 related articles for article (PubMed ID: 33455920)
1. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
2. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
Freites Nuñez DD; Leon L; Mucientes A; Rodriguez-Rodriguez L; Font Urgelles J; Madrid García A; Colomer JI; Jover JA; Fernandez-Gutierrez B; Abasolo L
Ann Rheum Dis; 2020 Nov; 79(11):1393-1399. PubMed ID: 32769150
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.
Clemente D; Udaondo C; de Inocencio J; Nieto JC; Del Río PG; Fernández AG; Palomo JA; Bachiller-Corral J; Lopez Robledillo JC; Millán Longo C; Leon L; Abasolo L; Boteanu A
Pediatr Rheumatol Online J; 2021 Nov; 19(1):162. PubMed ID: 34838054
[TBL] [Abstract][Full Text] [Related]
5. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Strangfeld A; Schäfer M; Gianfrancesco MA; Lawson-Tovey S; Liew JW; Ljung L; Mateus EF; Richez C; Santos MJ; Schmajuk G; Scirè CA; Sirotich E; Sparks JA; Sufka P; Thomas T; Trupin L; Wallace ZS; Al-Adely S; Bachiller-Corral J; Bhana S; Cacoub P; Carmona L; Costello R; Costello W; Gossec L; Grainger R; Hachulla E; Hasseli R; Hausmann JS; Hyrich KL; Izadi Z; Jacobsohn L; Katz P; Kearsley-Fleet L; Robinson PC; Yazdany J; Machado PM;
Ann Rheum Dis; 2021 Jul; 80(7):930-942. PubMed ID: 33504483
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
9. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
11. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study.
Sarzi-Puttini P; Marotto D; Caporali R; Montecucco CM; Favalli EG; Franceschini F; Fredi M; Balduzzi S; Bazzani C; Bongiovanni S; Giorgi V; Batticciotto A; Cappelli A; Balzarini P; Dagna L; Sartorelli S; Ravagnani V; Tamanini S; Farah S; Faggioli P; Castelnovo L; Lurati AM; Galli M; Salaffi F
J Autoimmun; 2021 Jan; 116():102545. PubMed ID: 32972804
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
15. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.
Hanberg JS; Fu X; Wang X; Patel NJ; Kawano Y; Schiff A; Kowalski EN; Cook CE; Vanni KMM; Guzzo K; Qian G; Bade KJ; Saavedra A; Venkat R; Srivatsan S; Zhang Y; Sparks JA; Wallace ZS
Lancet Rheumatol; 2024 Jan; 6(1):e21-e30. PubMed ID: 38258675
[TBL] [Abstract][Full Text] [Related]
16. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
Hasseli R; Mueller-Ladner U; Hoyer BF; Krause A; Lorenz HM; Pfeil A; Richter J; Schäfer M; Schmeiser T; Strangfeld A; Schulze-Koops H; Voll RE; Specker C; Regierer AC
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33479021
[TBL] [Abstract][Full Text] [Related]
17. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia.
Sharma C; Keen H
Intern Med J; 2019 Apr; 49(4):519-525. PubMed ID: 30230146
[TBL] [Abstract][Full Text] [Related]
18. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
19. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
Ann Rheum Dis; 2021 Apr; 80(4):527-538. PubMed ID: 33268442
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.
Moradi S; Masoumi M; Mohammadi S; Vafaeimanesh J; Mohseni M; Mahdavi H; Aryannejad A
Intern Emerg Med; 2021 Jun; 16(4):919-923. PubMed ID: 33128696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
